'Rulebook of microbial ecology': Pianists launch Concerto to treat eczema, protect crops and get rid of BO
The microbiome world, at least in drug R&D, has had some hiccups this year, with Flagship’s Kaleido Biosciences shutting down and DermBiont pivoting away from the world of microbes, but there’s always room for new innovation.
In steps Concerto Biosciences, which came out with a $23 million Series A this week. Merck KGaA’s VC arm, Safar Partners and Horizons Ventures are all backing the Cambridge, MA startup hoping to treat atopic dermatitis, protect crops and get rid of bad odor in those sweaty armpits.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 153,800+ biopharma pros reading Endpoints daily — and it's free.